---
title: "Multi-State Stem Cell Law Updates: What Changed On July 1, 2026 - Save My Fat"
description: "On July 1, 2026, Wyoming's Stem Cell Freedom Act (Senate File 48), codified at W.S. 33-26-202(b), took effect, allowing Wyoming physicians to..."
url: "https://savemyfat.com/multi-state-stem-cell-law-updates-july-1-2026/"
---

# Multi-State Stem Cell Law Updates: What Changed on July 1, 2026

#### Table of Contents

- [Oscar Tellez](https://savemyfat.com/author/oscartellez/)
- [July 26, 2026](https://savemyfat.com/2026/07/26/)
- 10:00 am

![Multi-state stem cell law updates: what changed on july 1, 2026](https://savemyfat.com/wp-content/uploads/2026/06/July-26-1024x1024.png)Multi-state stem cell law updates: what changed on july 1, 2026 2

On July 1, 2026, Wyoming’s Stem Cell Freedom Act took effect, adding another state to the patchwork of laws governing non-FDA-approved stem cell therapy. For physicians tracking this landscape, the practical questions are what actually changed, what stayed the same, and what none of these laws do. This update covers the July 1 change, the current five-state framework, and the federal rules that remain unchanged.

**TLDR**: On July 1, 2026, Wyoming’s Stem Cell Freedom Act (Senate File 48), codified at W.S. 33-26-202(b), took effect, allowing Wyoming physicians to administer non-FDA-approved autologous mesenchymal stem cell therapy with a licensing-discipline shield. Florida, Utah, California, and Nevada laws remained in place and unchanged. A critical point holds across all five states: these laws govern administering therapy or disclosure obligations, not tissue banking, which is a separate preservation activity. No state law changes federal regulation, and no adipose-derived product is FDA-approved for disease treatment. Banking preserves a patient’s own tissue under 21 CFR Part 1271; it is not a treatment and does not guarantee eligibility, access, or clinical benefit.

**Important Disclaimer:** Save My Fat does not provide FDA-approved treatments or cures for any disease or condition. No adipose-derived stem cell product currently has FDA approval for disease treatment. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.

---

State law in this area changes frequently, and accurate tracking matters for compliance. The sections below summarize the July 2026 status and link to the evergreen state-law map for ongoing reference.

## What Changed on July 1, 2026: Wyoming SF 48 Is Now in Effect

The change on July 1, 2026, was the effective date of Wyoming’s Stem Cell Freedom Act, Senate File 48, codified at W.S. 33-26-202(b). The law passed the Wyoming Legislature unanimously and was signed in March 2026. It allows a Wyoming physician to recommend and administer stem cell therapy using a patient’s own cells that is not FDA-approved, and it provides a shield against state licensing discipline for physicians who do so responsibly, subject to informed consent and medical-standard requirements.

Two features distinguish the Wyoming law. First, it is specifically limited to autologous mesenchymal stem cells, meaning cells derived from a patient’s own fat, bone marrow, or connective tissue, which is a different scope from states focused on perinatal cells. Second, it directs the Wyoming Board of Medicine to maintain a registry of physicians qualified to perform such therapy. The detailed provider overview of the Wyoming [Stem Cell Freedom Act](/wyoming-stem-cell-freedom-act-july-1-2026-physicians/) covers the obligations. Critically, like every law discussed here, SF 48 governs administering therapy, not banking.

## The Five-State Framework as of July 2026

As of July 2026, five states have notable stem cell laws, and they differ substantially in scope and approach. Wyoming, effective July 1, 2026, covers autologous mesenchymal stem cell therapy. Florida, under Section 458.3245 effective July 1, 2025, permits physicians to administer non-FDA-approved stem cell therapy within three named areas, orthopedics, wound care, and pain management, with disclosure and consent obligations, as detailed in the [Florida physician checklist](/florida-sb-1768-the-complete-physician-checklist/). Utah, under Utah Code Section 58-1-512, requires specific disclosure and consent for non-FDA-approved stem cell therapy and focuses on placental and perinatal cells and human cells and tissues, summarized in the [Utah disclosure law](/utah-stem-cell-disclosure-law-suppliers-and-provider/) overview.

California and Nevada round out the framework. California’s Business and Professions Code Section 684, in effect since 2017, requires physicians performing non-FDA-approved stem cell therapy to post and provide a specified notice, and it expressly excludes therapies meeting the federal minimal-manipulation criteria, as the [California disclosure law](/california-stem-cell-disclosure-law-what-providers/) overview explains. Nevada, under its Chapter 629 framework adopted in 2023, takes a permissive approach to non-FDA-approved biologics and, effective January 1, 2026, requires certain primary care providers to inform patients about stem cell storage and donation options. The evergreen [state-law map](/multi-state-stem-cell-law-map-where-your-state-stand/) tracks these in detail.

## State-by-State Status Table: July 2026

The table summarizes the five-state framework as of July 2026.

State Statute What it governs Scope Status

Wyoming W.S. 33-26-202(b) (SF 48) Administering non-FDA-approved therapy; physician licensing shield Autologous MSCs (fat, marrow, connective tissue) Effective July 1, 2026

Florida Section 458.3245 (SB 1768) Administering non-FDA-approved therapy; disclosure and consent Orthopedics, wound care, pain management Effective July 1, 2025; unchanged

Utah Section 58-1-512 Disclosure and consent for non-FDA-approved therapy Placental and perinatal cells; HCT/Ps 2024, amended 2026; unchanged

California B&P Section 684 Required patient notice; excludes minimal-manipulation HCT/Ps Non-FDA-approved HCT/P therapy In effect since 2017; unchanged

Nevada NRS Chapter 629 Permits non-FDA-approved biologics; provider storage disclosure Nonembryonic cells 2023; disclosure rule effective Jan 1, 2026

Across every row, the law concerns administering therapy or disclosure obligations, not tissue banking.

## What Has Not Changed at the Federal Level

No state law changes federal regulation, and that is the most important point for any physician. The FDA continues to regulate human cells and tissues under [21 CFR Part 1271](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271), and no adipose-derived product is FDA-approved for disease treatment. A state law that shields a physician from state licensing discipline does not alter federal law or FDA enforcement authority, and the tension between these state laws and federal regulation is well documented.

For banking specifically, the federal framework is what governs. Banking intact adipose tissue is handled under 21 CFR Part 1271, and it is a preservation activity distinct from the therapy administration these state laws address. A physician should not read any state therapy law as authorizing or regulating banking, because banking and administering therapy are different activities under different parts of the regulatory framework. This separation also matters for enforcement. The FDA has consistently treated administering non-FDA-approved cell products as distinct from preserving a patient’s own tissue, and a state shield against licensing discipline does nothing to change how the FDA approaches products that fall within its jurisdiction. For banking, the relevant question remains compliance with the federal tissue framework, not the contours of any state therapy law.

## States to Watch for 2027 Legislative Sessions

The trend of state-level stem cell legislation is likely to continue, and several states may consider bills in their 2027 sessions. The pattern so far has moved between two models: disclosure-focused laws, like those in California and Utah, and access-focused laws that shield physicians, like those in Florida and Wyoming. Physicians in states without current legislation should monitor their own legislatures, because this area is active.

Rather than predict specific outcomes, the practical approach is to track developments through a maintained resource and reassess compliance whenever a relevant law changes. The [state-law map](/multi-state-stem-cell-law-map-where-your-state-stand/) is updated as the landscape shifts. Whatever new laws emerge, the distinction between administering therapy and banking is likely to remain, and banking will continue to be governed by the federal tissue framework. Physicians can also expect continued attention from federal regulators and from professional bodies, which have generally urged caution about non-FDA-approved cell therapies regardless of state law. The prudent posture is to treat state authorization as narrow, to document carefully, and to keep banking clearly separated from any therapy a practice may or may not offer.

## Physician Action Checklist: July 2026 Compliance Review

A condensed compliance review for July 2026:

- Confirm which state’s law applies to the practice, and whether it is a disclosure-focused or access-focused law, using the correct statutory citation.
- For Wyoming, note that SF 48 is codified at W.S. 33-26-202(b) and took effect July 1, 2026, covering autologous mesenchymal stem cell therapy.
- Recognize that all five state laws govern administering therapy or disclosure, not banking, which remains a separate preservation activity.
- Maintain that no state law alters federal regulation under 21 CFR Part 1271, and that no adipose-derived product is FDA-approved for disease treatment.
- For banking specifically, confirm the banking partner operates under 21 CFR Part 1271 and keep banking documentation separate from any therapy records.

## Frequently Asked Questions

### What exactly changed on July 1, 2026?

Wyoming’s Stem Cell Freedom Act (Senate File 48), codified at W.S. 33-26-202(b), took effect. It allows Wyoming physicians to administer non-FDA-approved autologous mesenchymal stem cell therapy with a shield against state licensing discipline, subject to consent and medical-standard requirements.

### Do any of these state laws authorize adipose tissue banking?

No. All five state laws govern administering non-FDA-approved therapy or disclosure obligations, not tissue banking. Banking is a separate preservation activity governed by the federal framework under 21 CFR Part 1271.

### Does a state law override FDA regulation?

No. No state law changes federal regulation or FDA enforcement authority. The FDA continues to regulate human cells and tissues under 21 CFR Part 1271, and no adipose-derived product is FDA-approved for disease treatment.

### How is Wyoming’s law different from Florida’s?

Wyoming’s law covers autologous mesenchymal stem cells from a patient’s own tissue and shields physicians from licensing discipline, while Florida’s law permits administration within three named areas, orthopedics, wound care, and pain management, with disclosure and consent obligations. Both govern administering therapy, not banking.

### How is adipose tissue banking regulated?

Banked adipose tissue is handled under 21 CFR Part 1271, the federal framework governing screening, processing, and storage of human cells and tissues, regardless of state therapy laws.

## Key Takeaways

For physicians tracking the state landscape, July 2026 added Wyoming to a five-state framework without changing the fundamentals. Wyoming’s Stem Cell Freedom Act, codified at W.S. 33-26-202(b), took effect July 1, 2026, allowing physicians to administer non-FDA-approved autologous mesenchymal stem cell therapy with a licensing shield, while Florida, Utah, California, and Nevada laws remained unchanged. The decisive point across all five states is that these laws govern administering therapy or disclosure, not tissue banking, which is a separate preservation activity. No state law alters federal regulation under 21 CFR Part 1271, and no adipose-derived product is FDA-approved for disease treatment. Above all, banking adipose tissue is a preservation service for potential future use; it is not a treatment, and it does not guarantee eligibility, access, or clinical benefit.

Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.

Physicians reviewing their compliance posture can consult the state-law map and [contact the team](/contact-us/) to discuss how banking fits a practice.

---

*Save My Fat partners with a U.S.-based tissue bank for laboratory processing and storage.*

*This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review is required before publication. Please consult your physician before making any decisions about treatment or research participation.*

**About the author:** Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent more than a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.

**Related guide:** [state stem cell laws](https://savemyfat.com/state-stem-cell-laws/).

[PrevPreviousWhat Informed Consent for Adipose Banking Actually Covers](https://savemyfat.com/what-informed-consent-for-adipose-banking-covers/)

[NextAdipose Banking for Multiple Sclerosis Patients: What to KnowNext](https://savemyfat.com/adipose-banking-for-multiple-sclerosis-patients/)

Providers

### [Urologist Guide to Adipose Banking and the Erectile Dysfunction Research Landscape](https://savemyfat.com/erectile-dysfunction-research-adipose-banking/)

 [Read More »](https://savemyfat.com/erectile-dysfunction-research-adipose-banking/)

Oscar Tellez 08/23/2026 10:00 AM

Providers

### [Dermatologist Guide to Adipose Banking: What the Research Landscape Looks Like in 2026](https://savemyfat.com/dermatologist-adipose-banking-guide/)

 [Read More »](https://savemyfat.com/dermatologist-adipose-banking-guide/)

Oscar Tellez 08/22/2026 10:00 AM

Clinical Trials

### [What Happens If a Clinical Trial for Adipose-Derived Cells Is Terminated Early](https://savemyfat.com/terminated-clinical-trial-what-it-means/)

 [Read More »](https://savemyfat.com/terminated-clinical-trial-what-it-means/)

Oscar Tellez 08/21/2026 10:00 AM

Clinical Trials

### [The Multiple System Atrophy Trial Landscape Beyond Mayo Clinic: What Else Is Being Studied](https://savemyfat.com/multiple-system-atrophy-clinical-trials-2026/)

 [Read More »](https://savemyfat.com/multiple-system-atrophy-clinical-trials-2026/)

Oscar Tellez 08/20/2026 10:00 AM

Regulation

### [Ryoncil in 2026: What Changed Since the First FDA-Approved MSC Therapy](https://savemyfat.com/ryoncil-2026-update-first-approved-msc-therapy/)

 [Read More »](https://savemyfat.com/ryoncil-2026-update-first-approved-msc-therapy/)

Oscar Tellez 08/19/2026 10:00 AM

Clinical Trials

### [NCT06002841 Explained: What This Registered Clinical Trial Is Studying](https://savemyfat.com/extracellular-vesicle-trial-nct06002841/)

 [Read More »](https://savemyfat.com/extracellular-vesicle-trial-nct06002841/)

Oscar Tellez 08/18/2026 10:00 AM

```json
[{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"#article","headline":"Multi-State Stem Cell Law Updates: What Changed On July 1, 2026 - Save My Fat","name":"Multi-State Stem Cell Law Updates: What Changed On July 1, 2026 - Save My Fat","datePublished":"2026-07-26T10:00:00-04:00","dateModified":"2026-08-05T14:45:28-04:00","description":"On July 1, 2026, Wyoming's Stem Cell Freedom Act (Senate File 48), codified at W.S. 33-26-202(b), took effect, allowing Wyoming physicians to...","inLanguage":"en-US","image":"https:\/\/savemyfat.com\/wp-content\/uploads\/2026\/06\/July-26.png","isPartOf":{"@id":"#webpage"},"author":{"@type":"Person","@id":"https:\/\/savemyfat.com\/oscar-tellez\/#person","name":"Oscar Tellez","jobTitle":"Founder","url":"https:\/\/savemyfat.com\/oscar-tellez"},"publisher":{"@type":"Organization","@id":"https:\/\/savemyfat.com\/#organization","name":"SaveMyFat","url":"https:\/\/savemyfat.com"},"articleSection":"Adipose Banking, Providers, Regulation, Stem Cells"},{"@type":"Organization","@id":"https:\/\/savemyfat.com\/#organization","name":"Save My Fat","sameAs":["https:\/\/www.facebook.com\/savemyfat\/","https:\/\/www.linkedin.com\/company\/save-my-fat","https:\/\/www.instagram.com\/savemyfat\/","https:\/\/search.sunbiz.org\/Inquiry\/CorporationSearch\/SearchResultDetail?inquirytype=EntityName&directionType=Initial&searchNameOrder=SAVEMYFAT%20L260000005000&aggregateId=flal-l26000000500-32d6bf22-6788-4c6f-a062-b944408d7cda&searchTerm=SAVE%20MY%20LLC&listNameOrder=SAVEMY%20L250004108200"],"logo":{"@type":"ImageObject","@id":"https:\/\/savemyfat.com\/#logo","url":"https:\/\/savemyfat.com\/wp-content\/uploads\/2025\/12\/Blk-Txt-Blk-BG-SMF.svg","contentUrl":"https:\/\/savemyfat.com\/wp-content\/uploads\/2025\/12\/Blk-Txt-Blk-BG-SMF.svg","caption":"Save My Fat","inLanguage":"en-US","width":"500","height":"500"}},{"@type":"WebSite","@id":"https:\/\/savemyfat.com\/#website","url":"https:\/\/savemyfat.com","name":"Save My Fat","alternateName":"https:\/\/savemyfat.com","publisher":{"@id":"https:\/\/savemyfat.com\/#organization"},"inLanguage":"en-US"},{"@type":"ImageObject","@id":"https:\/\/savemyfat.com\/wp-content\/uploads\/2026\/06\/July-26.png","url":"https:\/\/savemyfat.com\/wp-content\/uploads\/2026\/06\/July-26.png","width":"1050","height":"1050","caption":"Multi-State Stem Cell Law Updates: What Changed on July 1, 2026","inLanguage":"en-US"},{"@type":"BreadcrumbList","@id":"https:\/\/savemyfat.com\/multi-state-stem-cell-law-updates-july-1-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":"1","item":{"@id":"https:\/\/savemyfat.com","name":"Home"}},{"@type":"ListItem","position":"2","item":{"@id":"https:\/\/savemyfat.com\/our-blog\/","name":"Our Blog"}},{"@type":"ListItem","position":"3","item":{"@id":"https:\/\/savemyfat.com\/category\/adipose-banking\/","name":"Adipose Banking"}},{"@type":"ListItem","position":"4","item":{"@id":"https:\/\/savemyfat.com\/multi-state-stem-cell-law-updates-july-1-2026\/","name":"Multi-State Stem Cell Law Updates: What Changed on July 1, 2026"}}]},{"@type":["WebPage","FAQPage"],"@id":"https:\/\/savemyfat.com\/multi-state-stem-cell-law-updates-july-1-2026\/#webpage","url":"https:\/\/savemyfat.com\/multi-state-stem-cell-law-updates-july-1-2026\/","name":"Multi-State Stem Cell Law Updates: What Changed On July 1, 2026 - Save My Fat","datePublished":"2026-07-26T10:00:00-04:00","dateModified":"2026-08-05T14:45:28-04:00","isPartOf":{"@id":"https:\/\/savemyfat.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/savemyfat.com\/wp-content\/uploads\/2026\/06\/July-26.png"},"inLanguage":"en-US","breadcrumb":{"@id":"https:\/\/savemyfat.com\/multi-state-stem-cell-law-updates-july-1-2026\/#breadcrumb"},"mainEntity":[{"@type":"Question","name":"What is adipose tissue banking?","acceptedAnswer":{"@type":"Answer","text":"Adipose tissue banking is the process of collecting, processing, and cryopreserving your own body fat for potential future use in FDA-regulated clinical research, Expanded Access programs, or approved therapies. It is a preservation service, not a treatment."}},{"@type":"Question","name":"Is adipose tissue banking FDA-approved?","acceptedAnswer":{"@type":"Answer","text":"Tissue banking as a preservation service is not a product requiring FDA approval. However, any future medical use of stored tissue must comply with FDA regulations at that time. Products derived from adipose tissue that undergo more than minimal manipulation typically require IND applications and a Biologics License Application before legal marketing."}}]}]},{"@context":"https:\/\/schema.org","@graph":[{"@type":"Person","@id":"https:\/\/savemyfat.com\/oscar-tellez\/#person","name":"Oscar Tellez","jobTitle":"Founder","description":"Oscar Tellez is the Founder of SaveMyFat, a national adipose tissue banking company that helps individuals preserve their own fat-derived stem cells for potential future use in FDA-regulated research pathways.","url":"https:\/\/savemyfat.com\/oscar-tellez","email":"info@savemyfat.com","image":{"@type":"ImageObject","url":"https:\/\/savemyfat.com\/wp-content\/uploads\/2026\/05\/Oscar-Headshot-Rounded-1.png","width":"200","height":"200"},"worksFor":{"@type":"Organization","@id":"https:\/\/savemyfat.com\/#organization","name":"SaveMyFat","url":"https:\/\/savemyfat.com"},"knowsAbout":["Adipose Tissue Banking","Stem Cell Cryopreservation","Regenerative Medicine","Fat-Derived Stem Cells","Expanded Access Pathways"],"sameAs":["https:\/\/savemyfat.com\/oscar-tellez","https:\/\/www.linkedin.com\/in\/o-tellez\/","https:\/\/www.facebook.com\/savemyfat\/","https:\/\/www.instagram.com\/savemyfat\/"]},{"@type":"Article","headline":"Multi-State Stem Cell Law Updates: What Changed on July 1, 2026","url":"https:\/\/savemyfat.com\/multi-state-stem-cell-law-updates-july-1-2026\/","datePublished":"2026-07-26T10:00:00-04:00","dateModified":"2026-08-05T14:45:28-04:00","description":"On July 1, 2026, Wyoming's Stem Cell Freedom Act (Senate File 48), codified at W.S. 33-26-202(b), took effect, allowing Wyoming physicians to administer non-FDA-approved autologous mesenchymal stem cell therapy with a licensing-discipline shield. Florida, Utah, California, and Nevada laws remained in place and unchanged. A critical point holds across all five states: these laws govern administering therapy or disclosure obligations, not tissue banking, which is a separate preservation activity. No state law changes federal regulation, and no adipose-derived product is FDA-approved for disea...","abstract":"On July 1, 2026, Wyoming's Stem Cell Freedom Act (Senate File 48), codified at W.S. 33-26-202(b), took effect, allowing Wyoming physicians to administer non-FDA-approved autologous mesenchymal stem cell therapy with a licensing-discipline shield. Florida, Utah, California, and Nevada laws remained in place and unchanged. A critical point holds across all five states: these laws govern administering therapy or disclosure obligations, not tissue banking, which is a separate preservation activity. No state law changes federal regulation, and no adipose-derived product is FDA-approved for disea...","author":{"@type":"Person","@id":"https:\/\/savemyfat.com\/oscar-tellez\/#person","name":"Oscar Tellez","jobTitle":"Founder","url":"https:\/\/savemyfat.com\/oscar-tellez"},"publisher":{"@type":"Organization","@id":"https:\/\/savemyfat.com\/#organization","name":"SaveMyFat","url":"https:\/\/savemyfat.com"},"speakable":{"@type":"SpeakableSpecification","cssSelector":["#tldr-summary"],"xpath":["\/\/*[@id=\"tldr-summary\"]"]}}]}]
```